GZR33 clinical trials
How each study uses GZR33 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GZR33 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Gan and Lee Pharmaceuticals, USA (3) · Gan & Lee Pharmaceuticals. (2)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test GZR33.
Studies
Open first, then newest update. How each study uses GZR33 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin AspartNot yet recruitingPhase 1Gan & Lee Pharmaceuticals.NCT07918898Written as GZR33 Injection
- Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 DiabetesRecruitingPhase 3Gan & Lee Pharmaceuticals.NCT07527078Written as GZR33 Injection
- Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady StateRecruitingPhase 1Gan and Lee Pharmaceuticals, USANCT07242664Written as GZR-33
- A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection ODRecruitingPhase 2Gan and Lee Pharmaceuticals, USANCT06558708Written as GZR33 Injection
- A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult SubjectsCompletedPhase 1Gan and Lee Pharmaceuticals, USANCT06548932Written as GZR33 Injection